Sigma-Aldrich will supply services to and exclusively provide custom oligonucleotides to Gene Oracle. The companies co-market GeneIOS gene synthesis system and services.


Sigma-Aldrich’s oligonucleotides thus becomes a key component of the Gene Oracle gene-synthesis platform. After customers design an optimized gene sequence using the GeneIOS software, Sigma-Aldrich reports that it will generate high-quality oligonucleotides that can be assembled to create synthetic genes within a single day.

Previous articleBioVex Bags $40M for Late-Stage Trial with Oncolytic Virus Technology
Next articleUT Investigators to Research Antibodies with Regeneron VelocImmune Technology